CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy

Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmas, Ezgi, Saljoughian, Noushin, de Souza Fernandes Pereira, Marcelo, Tullius, Brian P., Sorathia, Kinnari, Nakkula, Robin J., Lee, Dean A., Naeimi Kararoudi, Meisam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016158/
https://www.ncbi.nlm.nih.gov/pubmed/35449580
http://dx.doi.org/10.3389/fonc.2022.834002
_version_ 1784688468705673216
author Elmas, Ezgi
Saljoughian, Noushin
de Souza Fernandes Pereira, Marcelo
Tullius, Brian P.
Sorathia, Kinnari
Nakkula, Robin J.
Lee, Dean A.
Naeimi Kararoudi, Meisam
author_facet Elmas, Ezgi
Saljoughian, Noushin
de Souza Fernandes Pereira, Marcelo
Tullius, Brian P.
Sorathia, Kinnari
Nakkula, Robin J.
Lee, Dean A.
Naeimi Kararoudi, Meisam
author_sort Elmas, Ezgi
collection PubMed
description Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects.
format Online
Article
Text
id pubmed-9016158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90161582022-04-20 CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy Elmas, Ezgi Saljoughian, Noushin de Souza Fernandes Pereira, Marcelo Tullius, Brian P. Sorathia, Kinnari Nakkula, Robin J. Lee, Dean A. Naeimi Kararoudi, Meisam Front Oncol Oncology Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects. Frontiers Media S.A. 2022-04-05 /pmc/articles/PMC9016158/ /pubmed/35449580 http://dx.doi.org/10.3389/fonc.2022.834002 Text en Copyright © 2022 Elmas, Saljoughian, de Souza Fernandes Pereira, Tullius, Sorathia, Nakkula, Lee and Naeimi Kararoudi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Elmas, Ezgi
Saljoughian, Noushin
de Souza Fernandes Pereira, Marcelo
Tullius, Brian P.
Sorathia, Kinnari
Nakkula, Robin J.
Lee, Dean A.
Naeimi Kararoudi, Meisam
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title_full CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title_fullStr CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title_full_unstemmed CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title_short CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
title_sort crispr gene editing of human primary nk and t cells for cancer immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016158/
https://www.ncbi.nlm.nih.gov/pubmed/35449580
http://dx.doi.org/10.3389/fonc.2022.834002
work_keys_str_mv AT elmasezgi crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT saljoughiannoushin crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT desouzafernandespereiramarcelo crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT tulliusbrianp crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT sorathiakinnari crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT nakkularobinj crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT leedeana crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy
AT naeimikararoudimeisam crisprgeneeditingofhumanprimarynkandtcellsforcancerimmunotherapy

Ejemplares similares